Vertex Pharmaceuticals reports $3.33 billion revenue for quarter ended June 30, 2026, up 12.5%
Vertex Pharmaceuticals reported revenue of $3.33 billion for the quarter ended June 30, 2026, an increase of 12.5% from the same quarter a year earlier ($2.96 billion).
For the same period it posted net income of $1.1 billion, up 6.5%, or $4.31 per diluted share (3.99 a year earlier).
That is a net margin of 33%.
On Sanad's AAOIFI Standard 21 screen, Vertex Pharmaceuticals is currently compliant: interest-bearing debt is 3.3% of market capitalisation (limit 30%), and impure income is 4.1% of revenue (limit 5%).
Is Vertex Pharmaceuticals halal?
See the full AAOIFI screening of Vertex Pharmaceuticals
See the full AAOIFI screening of Vertex Pharmaceuticals
Source: 10-Q filed with the U.S. Securities and Exchange Commission on August 4, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.